Encephalomyelitis - Pipeline Review, H2 2020
Encephalomyelitis - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2020, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.
Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2020, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.
Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Encephalomyelitis - Overview
Encephalomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalomyelitis - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
Inflazome Ltd
K-Pax Pharmaceuticals Inc
Orion BioScience Inc
Philogen SpA
Encephalomyelitis - Drug Profiles
CT-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JM-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalomyelitis - Dormant Projects
Encephalomyelitis - Product Development Milestones
Featured News & Press Releases
Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Encephalomyelitis - Overview
Encephalomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalomyelitis - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
Inflazome Ltd
K-Pax Pharmaceuticals Inc
Orion BioScience Inc
Philogen SpA
Encephalomyelitis - Drug Profiles
CT-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JM-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalomyelitis - Dormant Projects
Encephalomyelitis - Product Development Milestones
Featured News & Press Releases
Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Encephalomyelitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Encephalomyelitis - Pipeline by AIM ImmunoTech Inc, H2 2020
Encephalomyelitis - Pipeline by Biovista Inc, H2 2020
Encephalomyelitis - Pipeline by Cortene Inc, H2 2020
Encephalomyelitis - Pipeline by Inflazome Ltd, H2 2020
Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, H2 2020
Encephalomyelitis - Pipeline by Orion BioScience Inc, H2 2020
Encephalomyelitis - Pipeline by Philogen SpA, H2 2020
Encephalomyelitis - Dormant Projects, H2 2020
Encephalomyelitis - Dormant Projects, H2 2020 (Contd..1), H2 2020
Number of Products under Development for Encephalomyelitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Encephalomyelitis - Pipeline by AIM ImmunoTech Inc, H2 2020
Encephalomyelitis - Pipeline by Biovista Inc, H2 2020
Encephalomyelitis - Pipeline by Cortene Inc, H2 2020
Encephalomyelitis - Pipeline by Inflazome Ltd, H2 2020
Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, H2 2020
Encephalomyelitis - Pipeline by Orion BioScience Inc, H2 2020
Encephalomyelitis - Pipeline by Philogen SpA, H2 2020
Encephalomyelitis - Dormant Projects, H2 2020
Encephalomyelitis - Dormant Projects, H2 2020 (Contd..1), H2 2020
LIST OF FIGURES
Number of Products under Development for Encephalomyelitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
Inflazome Ltd
K-Pax Pharmaceuticals Inc
Orion BioScience Inc
Philogen SpA
Number of Products under Development for Encephalomyelitis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
Inflazome Ltd
K-Pax Pharmaceuticals Inc
Orion BioScience Inc
Philogen SpA
